Background: Although neuroAIDS or AIDS dementia caused by HIV-1 has been declining in clinical practice due to the use of Highly Active Antiretroviral Therapy (HAART), a milder neurologic disorder termed Minor Cognitive Motor Disorder (MCMD) continues to be a significant clinical problem. To develop new strategies to intervene in HIV disease progression in the brain, our lab has been developing a novel nonhuman primate neuroAIDS model by in vivo passage of SIVsmE543-3, a strain that is capable of inducing AIDS in the infected rhesus macaques but not SIV encephalitis (SIVE). As a result, we have recently isolated a viral strain, SIVsm804E, which can cause neuroAIDS in infected animals at high frequencies (Matsuda et al., JVI 2013, Matsuda et al., JVI 2014). A molecular clone, SIVsm804E CL757 was then isolated from the SIVsm804E viral swarm. Introduction of the gp41 cytoplasmic tail of Env of this molecular clone into the parental SIVsmE543-3 backbone, resulted in improvement of viral replication in monocyte derived macrophages (MDMs) in vitro. It has been previously reported that the cytoplasmic tail of gp41 of SIV plays an important role in the antagonism of the host factor, bone marrow stromal antigen 2 (BST-2, also known as Tetherin), that impairs the release of nascent viral particles from the virus-producing cells (Serra-Moreno et al., Cell host microbes 2011).
Methods: To determine whether efficient antagonism of BST-2 is responsible for the improvement of replication in macrophages, pulse-chase and immmunoprecipitation assays were conducted to compare the efficacy of BST-2 antagonism by the original SIVsmE543 to that of a variant with the cytoplasmic tail mutations found in SIVsm804E CL757.
Results: Preliminary data show that multiple mutations in the cytoplasmic tail of gp41 individually enhance viral release from the cells expressing BST-2. Since macrophages are the main target for viral infection and replication in the brain of SIV infected animals, our results suggest that our virus acquired mutations in the cytoplasmic tail of gp41 for efficient replication in the central nervous system (CNS).
Conclusions: Although SIV and HIV-1 utilize different viral proteins to antagonize BST-2, our data suggest that BST-2 may play an important role in the suppression of viral replication in the CNS and intervention of viral factors that antagonize BST-2 could be a novel strategy for prevention of disease progression in the CNS during HAART.